english          中文


The following Autism studies are now recruiting in Nottinghamshire Healthcare NHS Foundation Trust:

The SHAPE project: Supporting adults with high-functioning autism and asperger syndrome. Mapping and evaluating Specialist Autism Team service models.

Principal Investigator: Dr Bryony Beresford

Study Summary: The SHAPE Project is a national research study evaluating specialist Autism teams. The purpose is to investigate the best way of running and providing a specialist autism team. Nine specialist autism teams across the country are participating, and the study will evaluate the outcomes for clients via questionnaires and interviews, as well as consulting with carers and the professionals working within the service.

Inclusion criteria:

  • Referral to Specialist Autism Team (Nottingham City Asperger Service)
  • Diagnosed with Asperger Syndrome or referred for a diagnosis of Asperger Syndrome

Exclusion criteria:

  • Other neurodevelopmental condition (eg ADHD).
  • known intellectual disability

Lead Research Delivery Officer: Natalie Marking, This email address is being protected from spambots. You need JavaScript enabled to view it., 07769 235483

The mATCH study: People with AuTism detained within hospitals: defining the population, understanding aetiology and improving Care patHways (The mATCH study).

Principal Investigator: Highbury IDD - Dr Deval Bagalkote

Principal Investigator: Wells Road Centre (Forensics) - Dr Abdul Shaikh

This study has three aims:

  1. To further develop a proposed sub-typology for people with autistic spectrum disorders (ASD) detained within hospital.
  2. To test the validity of these subtypes, by examining the relationship between these subtypes, clinical data, and neurocognitive variables.
  3. To examine the relationship between these subtypes and patient outcome in order to understand the most appropriate care pathway.

The aims will be investigated within three related workstreams:

  1. Workstream I will involve using focus group work and consensus methods with clinicians and services users to refine our sub-typology. Clinicians will then be asked to rate all their current inpatients with ASD according to the subtypes.
  2. Workstream II will involve examining the validity of our subtypes within two sub-streams: i) Workstream IIa will involve collecting data about behaviour, resource use and risk from clinical records and staff members, describing factors related to care-pathways, and then making comparisons between subtypes on a minimum of 150 patients, and ii) Workstream IIb will involve asking 100 of these patients to complete a battery of neurocognitive tests to allow us to test the validity of our subtypes further. It is anticipated that differences between the subtypes can be characterised by key indicators (e.g. aggression and psychopathy).
  3. Workstream III involves those patients from Workstream IIa being followed up in 12 months, allowing us to collect behavioural data over time. This will allow us to examine how outcome differs between our subtypes, and whether the care pathway differs between subtypes.

Potential Benefits to Patients:

This study has direct implications for hospital care pathways. Importantly, the study will also allow us to examine the differences between patients, describe their care needs more effectively, and design better hospital care pathways. This project will help the NHS to understand patients with ASD who are detained within hospital effectively, consider risk more appropriately and design better in-patient services and care pathways to the community. This will directly benefit patients by minimising the risk of them being in restrictive hospital settings for longer than necessary.

Lead Research Delivery Officer: Amy Shuttlewood, This email address is being protected from spambots. You need JavaScript enabled to view it. 07769 235481